Comparison of lenvatinib plus pembrolizumab versus firstline systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: A real-world retrospective study

被引：0
|
作者：
Yang, Z. [1 ]
Hu, D. [1 ]
Chen, M. [1 ]
机构：
[1] Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.449
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
306P
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [11] Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real- world study
    Ning, Zhouyu
    Xie, Lin
    Yan, Xia
    Hua, Yongqiang
    Shi, Weidong
    Lin, Junhua
    Xu, Litao
    Meng, Zhiqiang
    BRITISH JOURNAL OF RADIOLOGY, 2023, 96 (1150):
  • [12] Lenvatinib plus pembrolizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma: A real world study.
    Lee, I-Cheng
    Wu, Chi-Jung
    Chen, San-Chi
    Chao, Yee
    Huang, Yi-Hsiang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [13] Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study
    Zhao, Lei
    Chang, Niajia
    Shi, Lei
    Li, Fengyi
    Meng, Fanglin
    Xie, Xiaohui
    Xu, Zhe
    Wang, Fusheng
    HELIYON, 2022, 8 (06)
  • [14] Real-world comparison of neoadjuvant pembrolizumab plus chemotherapy versus tislelizumab plus chemotherapy in patients with resectable non-small cell lung cancer: a retrospective cohort study of treatment outcomes
    Hu, Yan
    Ren, Siying
    Feng, Juan
    Zeng, Chao
    Yang, Lulu
    Liu, Jinyou
    Wu, Fang
    Liu, Wenliang
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (02)
  • [15] A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
    Fujimoto, Daichi
    Miura, Satoru
    Yoshimura, Kenichi
    Wakuda, Kazushige
    Oya, Yuko
    Haratani, Koji
    Itoh, Shoichi
    Uemura, Takehiro
    Morinaga, Ryotaro
    Takahama, Takayuki
    Nakashima, Kazuhisa
    Tachihara, Motoko
    Saito, Go
    Tanizaki, Junko
    Otsubo, Kohei
    Ikeda, Satoshi
    Matsumoto, Hirotaka
    Hara, Satoshi
    Hata, Akito
    Masuda, Takeshi
    Yamamoto, Nobuyuki
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (02):
  • [16] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [17] Real-world experience of pembrolizumab plus lenvatinib in unresectable hepatocellular carcinoma in Taiwan.
    Wu, Chi-Jung
    Hung, Ya-Wen
    Lee, Pei-Chang
    Lee, ChiehJu
    Chen, Ming Huang
    Chao, Yee
    Hou, Ming-Chih
    Huang, Yi-Hsiang
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [18] Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma.
    Shi, Guo-Ming
    Jian, Zhou
    Fan, Jia
    Huang, Xiao-Yong
    Wu, Dong
    Liang, Fei
    Lu, Jia-Cheng
    Yang, Guo-Huan
    Chen, Yi
    Ge, Ning-Ling
    Ji, Yuan
    Hou, Y. Y.
    Sun, Hui-Chuan
    Qiu, Shuang-Jian
    Ye, Qing-Hai
    Huang, Xiao-Wu
    Shi, Ying-Hong
    Gao, Qiang
    Yang, Xin-Rong
    Wang, Zheng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [19] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [20] Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review
    Zhang, Wei
    Luo, Chu
    Zhang, Zun-Yi
    Zhang, Bi-Xiang
    Chen, Xiao-Ping
    FRONTIERS IN IMMUNOLOGY, 2023, 13
12345